MedWatch

Copy-manufacturer: ”We can’t just make it out back”

Medicine manufacturers concede that they will never be able to create biosimilar drugs at the same low prices as generic versions of chemical compounds, but there is still money to be saved. A consultant doctor and professor at a Danish hospital is cautious about the use of biosimilars instead of patented medicine.

Foto: Colourbox

Society as a whole will never save as much money from using biosimilar medicine, as has been the case with chemical drugs. The cost of producing biosimilars is simply too high.

That was the conclusion when the pharmaceutical industry, authorities, patients and doctors gathered last week at the offices of The Danish Association of the Pharmaceutical Industry (Lif) to discuss the future of biological drugs and the cheaper, generic versions of these known as biosimilars.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Dansk Biotek skifter navn

Den danske brancheorganisation for biotekselskaber, Dansk Biotek, skifter navn til "Danish Bio - Dansk Biotek" for at imødekomme den stigende internationalisering af branchen, fortæller formand.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier